Full Press Release Details
LifeSciences, Inc. Announces Pricing of Initial Public Offering
TX / [Business Wire] / September 24, 2020 / Greenwich LifeSciences, Inc. (the "Company"), a clinical-stage
biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients
who have previously undergone surgery, today announced the pricing of its initial public offering of 1,260,870 shares of its common
stock at a public offering price of $5.75 per share for gross proceeds of $7,250,002, before deducting offering expenses. In addition,
the Company has granted the underwriter a 45-day option to purchase up to 189,130 additional shares of common stock at the public
offering price, less the underwriting discount, to cover over-allotments, if any. The shares are expected to begin trading on The
Nasdaq Capital Market on September 25, 2020, under the symbol "GLSI."
Capital Corp. is acting as the sole book running manager.
registration statement relating to the shares of common stock being sold in this offering was declared effective by the Securities
and Exchange Commission (the "SEC") on September 24, 2020. The offering is being made only by means of a prospectus.
Copies of the final prospectus may be obtained, when available, on the SEC's website, www.sec.gov, or by contacting Aegis
Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY 10019,
by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010.
press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be
any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or jurisdiction.
Breast Cancer and HER2/neu Positivity
in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients
and 3.1 million breast cancer survivors in 2018. HER2/neu (human epidermal growth factor receptor 2) protein is a cell
surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate
(2+), and high (3+ or over-expressor) levels.
Greenwich LifeSciences, Inc.
LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast
cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu
protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb
clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the
patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have
been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed
related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment
regime as the Phase IIb clinical trial.
Statement Disclaimer
statements in this press release constitute "forward-looking statements" within the meaning of the federal securities
laws. Words such as "may," "might," "will," "should," "believe," "expect,"
"anticipate," "estimate," "continue," "predict," "forecast," "project,"
"plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations,
including the Company's expectations regarding the proposed offering of the Company's shares of common stock, including
as to the consummation of the offering described above and the size of the offering are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements,
which are based on information available to the Company on the date of this release. These forward looking statements are based
upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those
set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company expressly disclaims
any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required
& Public Relations Team
Source: Greenwich LifeSciences, Inc.